Drugs / piribedil
piribedil
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT01007864 | Jan 2010 → Dec 2011 | Parkinson disease | Desitin Arzneimittel GmbH | Completed | No outcome recorded |
| Phase not applicable1 trial · 1 missed | ||||||
| — | NCT00591994 | Nov 2006 → Dec 2007 | tinnitus | Faculdade de Medicina de Valenca | Completed | Missed primary |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | piribedil | “The purpose of this clinical trial is to investigate the effects of the non-ergot dopamine agonist piribedil on vigilance and cognitive performances in patients with...” NCT01007864 ↗ |
| Known as | ET-495 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1371770 ↗ |
| Known as | EU-4200 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1371770 ↗ |
| Known as | Trivastal | ChEMBL registry synonym — accepted as the source's own label CHEMBL1371770 ↗ |
| Known as | Trivastal lp | ChEMBL registry synonym — accepted as the source's own label CHEMBL1371770 ↗ |
| Modality | Small molecule | — CHEMBL1371770 ↗ |
| Route | Oral | “Oral application of piribedil” NCT01007864 ↗ |